LU85711A1 - Acylaminomitosanes - Google Patents

Acylaminomitosanes Download PDF

Info

Publication number: LU85711A1
Authority: LU; Luxembourg
Prior art keywords: compound according; amino; methoxymitosan; mitomycin; substituted
Prior art date: 1983-12-23

Application number

LU85711A

Other languages

English (en)

French (fr)

Original Assignee

Bristol Myers Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1983-12-23

Filing date

1984-12-21

Publication date

1985-09-12

1984-12-21 Application filed by Bristol Myers Co filed Critical Bristol Myers Co

1985-09-12 Publication of LU85711A1 publication Critical patent/LU85711A1/fr

Links

NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 111
150000001875 compounds Chemical class 0.000 claims description 75
229960004857 mitomycin Drugs 0.000 claims description 55
-1 iodo, amino, protected amino Chemical group 0.000 claims description 36
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 17
239000003795 chemical substances by application Substances 0.000 claims description 11
125000000129 anionic group Chemical group 0.000 claims description 9
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 8
125000003710 aryl alkyl group Chemical group 0.000 claims description 7
125000003118 aryl group Chemical group 0.000 claims description 6
238000000034 method Methods 0.000 claims description 6
238000002360 preparation method Methods 0.000 claims description 6
239000002904 solvent Substances 0.000 claims description 6
125000001424 substituent group Chemical group 0.000 claims description 6
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 4
125000004432 carbon atom Chemical group C* 0.000 claims description 4
239000003960 organic solvent Substances 0.000 claims description 4
125000000217 alkyl group Chemical group 0.000 claims description 3
125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 3
125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 2
125000005110 aryl thio group Chemical group 0.000 claims description 2
125000000638 benzylaminocarbonyl group Chemical group C(C1=CC=CC=C1)NC(=O)* 0.000 claims description 2
125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims description 2
125000000753 cycloalkyl group Chemical group 0.000 claims description 2
125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims description 2
125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims description 2
125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 2
UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims description 2
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 2
125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 claims description 2
125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 1
125000006619 (C1-C6) dialkylamino group Chemical group 0.000 claims 1
125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 claims 1
125000000882 C2-C6 alkenyl group Chemical class 0.000 claims 1
125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
125000000041 C6-C10 aryl group Chemical group 0.000 claims 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
125000004414 alkyl thio group Chemical group 0.000 claims 1
125000001246 bromo group Chemical group Br* 0.000 claims 1
125000001309 chloro group Chemical group Cl* 0.000 claims 1
125000001153 fluoro group Chemical group F* 0.000 claims 1
150000004678 hydrides Chemical class 0.000 claims 1
229910052708 sodium Inorganic materials 0.000 claims 1
239000011734 sodium Substances 0.000 claims 1
125000003396 thiol group Chemical class [H]S* 0.000 claims 1
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 26
238000006243 chemical reaction Methods 0.000 description 25
238000005481 NMR spectroscopy Methods 0.000 description 23
238000004458 analytical method Methods 0.000 description 20
229910000104 sodium hydride Inorganic materials 0.000 description 20
JUJWROOIHBZHMG-RALIUCGRSA-N pyridine-d5 Chemical compound [2H]C1=NC([2H])=C([2H])C([2H])=C1[2H] JUJWROOIHBZHMG-RALIUCGRSA-N 0.000 description 16
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 14
241000699670 Mus sp. Species 0.000 description 13
229910001868 water Inorganic materials 0.000 description 13
241001465754 Metazoa Species 0.000 description 12
230000000694 effects Effects 0.000 description 11
VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 11
238000004587 chromatography analysis Methods 0.000 description 10
239000000741 silica gel Substances 0.000 description 10
229910002027 silica gel Inorganic materials 0.000 description 10
230000000259 anti-tumor effect Effects 0.000 description 9
239000000126 substance Substances 0.000 description 9
230000004083 survival effect Effects 0.000 description 9
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 8
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 8
241000699666 Mus <mouse, genus> Species 0.000 description 7
206010028980 Neoplasm Diseases 0.000 description 7
WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 7
239000006185 dispersion Substances 0.000 description 7
238000002474 experimental method Methods 0.000 description 7
239000000203 mixture Substances 0.000 description 7
150000003254 radicals Chemical class 0.000 description 7
239000011541 reaction mixture Substances 0.000 description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
229930192392 Mitomycin Natural products 0.000 description 6
229910052757 nitrogen Inorganic materials 0.000 description 6
125000004433 nitrogen atom Chemical group N* 0.000 description 6
239000007787 solid Substances 0.000 description 6
MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 description 5
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 4
HYFMSAFINFJTFH-UHFFFAOYSA-N Mitomycin-A Natural products O=C1C(OC)=C(C)C(=O)C2=C1C(COC(N)=O)C1(OC)N2CC2NC21 HYFMSAFINFJTFH-UHFFFAOYSA-N 0.000 description 4
238000000862 absorption spectrum Methods 0.000 description 4
PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 4
239000001569 carbon dioxide Substances 0.000 description 4
229910002092 carbon dioxide Inorganic materials 0.000 description 4
235000019439 ethyl acetate Nutrition 0.000 description 4
238000000855 fermentation Methods 0.000 description 4
230000004151 fermentation Effects 0.000 description 4
201000001441 melanoma Diseases 0.000 description 4
HYFMSAFINFJTFH-NGSRAFSJSA-N mitomycin A Chemical compound O=C1C(OC)=C(C)C(=O)C2=C1[C@@H](COC(N)=O)[C@]1(OC)N2C[C@@H]2N[C@@H]21 HYFMSAFINFJTFH-NGSRAFSJSA-N 0.000 description 4
NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 4
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
239000000047 product Substances 0.000 description 4
238000003756 stirring Methods 0.000 description 4
239000007832 Na2SO4 Substances 0.000 description 3
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
239000003242 anti bacterial agent Substances 0.000 description 3
230000037396 body weight Effects 0.000 description 3
239000012267 brine Substances 0.000 description 3
230000005595 deprotonation Effects 0.000 description 3
238000010537 deprotonation reaction Methods 0.000 description 3
150000002148 esters Chemical class 0.000 description 3
239000007924 injection Substances 0.000 description 3
238000002347 injection Methods 0.000 description 3
238000011081 inoculation Methods 0.000 description 3
230000003039 myelosuppressive effect Effects 0.000 description 3
125000006503 p-nitrobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1[N+]([O-])=O)C([H])([H])* 0.000 description 3
229910052938 sodium sulfate Inorganic materials 0.000 description 3
235000011152 sodium sulphate Nutrition 0.000 description 3
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
239000007858 starting material Substances 0.000 description 3
238000004809 thin layer chromatography Methods 0.000 description 3
GSLTVFIVJMCNBH-UHFFFAOYSA-N 2-isocyanatopropane Chemical compound CC(C)N=C=O GSLTVFIVJMCNBH-UHFFFAOYSA-N 0.000 description 2
LOLKAJARZKDJTD-UHFFFAOYSA-N 4-Ethoxy-4-oxobutanoic acid Chemical compound CCOC(=O)CCC(O)=O LOLKAJARZKDJTD-UHFFFAOYSA-N 0.000 description 2
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
208000008342 Leukemia P388 Diseases 0.000 description 2
HRHKSTOGXBBQCB-UHFFFAOYSA-N Mitomycin E Natural products O=C1C(N)=C(C)C(=O)C2=C1C(COC(N)=O)C1(OC)C3N(C)C3CN12 HRHKSTOGXBBQCB-UHFFFAOYSA-N 0.000 description 2
NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
230000010933 acylation Effects 0.000 description 2
238000005917 acylation reaction Methods 0.000 description 2
125000003342 alkenyl group Chemical group 0.000 description 2
125000000304 alkynyl group Chemical group 0.000 description 2
150000008064 anhydrides Chemical group 0.000 description 2
150000001450 anions Chemical class 0.000 description 2
229940088710 antibiotic agent Drugs 0.000 description 2
239000012300 argon atmosphere Substances 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-M benzoate Chemical compound [O-]C(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-M 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
125000004122 cyclic group Chemical group 0.000 description 2
125000006310 cycloalkyl amino group Chemical group 0.000 description 2
239000003814 drug Substances 0.000 description 2
238000001704 evaporation Methods 0.000 description 2
230000008020 evaporation Effects 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
238000007912 intraperitoneal administration Methods 0.000 description 2
231100001231 less toxic Toxicity 0.000 description 2
239000007788 liquid Substances 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
HRHKSTOGXBBQCB-VFWICMBZSA-N methylmitomycin Chemical compound O=C1C(N)=C(C)C(=O)C2=C1[C@@H](COC(N)=O)[C@@]1(OC)[C@H]3N(C)[C@H]3CN12 HRHKSTOGXBBQCB-VFWICMBZSA-N 0.000 description 2
239000012299 nitrogen atmosphere Substances 0.000 description 2
239000012044 organic layer Substances 0.000 description 2
239000002504 physiological saline solution Substances 0.000 description 2
229950004406 porfiromycin Drugs 0.000 description 2
239000013641 positive control Substances 0.000 description 2
239000000377 silicon dioxide Substances 0.000 description 2
239000000243 solution Substances 0.000 description 2
238000001228 spectrum Methods 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
JFOIBTLTZWOAIC-UHFFFAOYSA-N (4-nitrophenyl) 2,2,2-trifluoroacetate Chemical compound [O-][N+](=O)C1=CC=C(OC(=O)C(F)(F)F)C=C1 JFOIBTLTZWOAIC-UHFFFAOYSA-N 0.000 description 1
FFGGSHSHUKFELB-UHFFFAOYSA-N (4-nitrophenyl) methanesulfonate Chemical compound CS(=O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 FFGGSHSHUKFELB-UHFFFAOYSA-N 0.000 description 1
CRTADXBPEXSZLH-UHFFFAOYSA-N (4-nitrophenyl)methyl benzoate Chemical compound C1=CC([N+](=O)[O-])=CC=C1COC(=O)C1=CC=CC=C1 CRTADXBPEXSZLH-UHFFFAOYSA-N 0.000 description 1
KKFDJZZADQONDE-UHFFFAOYSA-N (hydridonitrato)hydroxidocarbon(.) Chemical group O[C]=N KKFDJZZADQONDE-UHFFFAOYSA-N 0.000 description 1
ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
RMQSINXLELHUAE-UHFFFAOYSA-N 1-[chloro(ethylsulfanyl)phosphoryl]oxyethane Chemical compound CCOP(Cl)(=O)SCC RMQSINXLELHUAE-UHFFFAOYSA-N 0.000 description 1
BCMYXYHEMGPZJN-UHFFFAOYSA-N 1-chloro-2-isocyanatoethane Chemical compound ClCCN=C=O BCMYXYHEMGPZJN-UHFFFAOYSA-N 0.000 description 1
KKASGUHLXWAKEZ-UHFFFAOYSA-N 1-isothiocyanatopropane Chemical compound CCCN=C=S KKASGUHLXWAKEZ-UHFFFAOYSA-N 0.000 description 1
CFMZSMGAMPBRBE-UHFFFAOYSA-N 2-hydroxyisoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(O)C(=O)C2=C1 CFMZSMGAMPBRBE-UHFFFAOYSA-N 0.000 description 1
NGUUMHKSNSFLOS-UHFFFAOYSA-N 2-methoxyethyl hydrogen carbonate Chemical compound COCCOC(O)=O NGUUMHKSNSFLOS-UHFFFAOYSA-N 0.000 description 1
206010003445 Ascites Diseases 0.000 description 1
101150041968 CDC13 gene Proteins 0.000 description 1
XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 1
208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
UZUUQCBCWDBYCG-UHFFFAOYSA-N Mitomycin B Natural products O=C1C(OC)=C(C)C(=O)C2=C1C(COC(N)=O)C1(O)N2CC2C1N2C UZUUQCBCWDBYCG-UHFFFAOYSA-N 0.000 description 1
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
206010070863 Toxicity to various agents Diseases 0.000 description 1
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
150000001266 acyl halides Chemical class 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
125000003282 alkyl amino group Chemical group 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
235000010633 broth Nutrition 0.000 description 1
239000000872 buffer Substances 0.000 description 1
235000013877 carbamide Nutrition 0.000 description 1
125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
125000002668 chloroacetyl group Chemical group ClCC(=O)* 0.000 description 1
235000019365 chlortetracycline Nutrition 0.000 description 1
239000000470 constituent Substances 0.000 description 1
125000006254 cycloalkyl carbonyl group Chemical group 0.000 description 1
KQWGXHWJMSMDJJ-UHFFFAOYSA-N cyclohexyl isocyanate Chemical compound O=C=NC1CCCCC1 KQWGXHWJMSMDJJ-UHFFFAOYSA-N 0.000 description 1
YMGUBTXCNDTFJI-UHFFFAOYSA-N cyclopropanecarboxylic acid Chemical compound OC(=O)C1CC1 YMGUBTXCNDTFJI-UHFFFAOYSA-N 0.000 description 1
229940127089 cytotoxic agent Drugs 0.000 description 1
PIZLBWGMERQCOC-UHFFFAOYSA-N dibenzyl carbonate Chemical compound C=1C=CC=CC=1COC(=O)OCC1=CC=CC=C1 PIZLBWGMERQCOC-UHFFFAOYSA-N 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
238000001035 drying Methods 0.000 description 1
OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
238000001914 filtration Methods 0.000 description 1
GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 description 1
239000007943 implant Substances 0.000 description 1
238000002513 implantation Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
239000002054 inoculum Substances 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
239000012948 isocyanate Substances 0.000 description 1
150000002513 isocyanates Chemical class 0.000 description 1
YDNLNVZZTACNJX-UHFFFAOYSA-N isocyanatomethylbenzene Chemical compound O=C=NCC1=CC=CC=C1 YDNLNVZZTACNJX-UHFFFAOYSA-N 0.000 description 1
150000002540 isothiocyanates Chemical class 0.000 description 1
238000009533 lab test Methods 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
231100000225 lethality Toxicity 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
238000005259 measurement Methods 0.000 description 1
COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
206010061289 metastatic neoplasm Diseases 0.000 description 1
RIFHJAODNHLCBH-UHFFFAOYSA-N methanethione Chemical group S=[CH] RIFHJAODNHLCBH-UHFFFAOYSA-N 0.000 description 1
CXHHBNMLPJOKQD-UHFFFAOYSA-M methyl carbonate Chemical compound COC([O-])=O CXHHBNMLPJOKQD-UHFFFAOYSA-M 0.000 description 1
UZUUQCBCWDBYCG-DQRAMIIBSA-N mitomycin B Chemical compound O=C1C(OC)=C(C)C(=O)C2=C1[C@H](COC(N)=O)[C@]1(O)N2C[C@H]2[C@@H]1N2C UZUUQCBCWDBYCG-DQRAMIIBSA-N 0.000 description 1
238000002156 mixing Methods 0.000 description 1
CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
LKPFBGKZCCBZDK-UHFFFAOYSA-N n-hydroxypiperidine Chemical compound ON1CCCCC1 LKPFBGKZCCBZDK-UHFFFAOYSA-N 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
210000000440 neutrophil Anatomy 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
230000000269 nucleophilic effect Effects 0.000 description 1
VVWNENUJKRQDTB-UHFFFAOYSA-N o-ethyl methanethioate Chemical compound CCOC=S VVWNENUJKRQDTB-UHFFFAOYSA-N 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
150000005677 organic carbonates Chemical class 0.000 description 1
125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
238000002638 palliative care Methods 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
201000002094 pancreatic adenocarcinoma Diseases 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
AGUWUIVKDXDKBT-UHFFFAOYSA-N phenyl 2-chloroacetate Chemical compound ClCC(=O)OC1=CC=CC=C1 AGUWUIVKDXDKBT-UHFFFAOYSA-N 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
HDGICZVUXOQTPV-UHFFFAOYSA-N phenylsulfanyl acetate Chemical compound CC(=O)OSC1=CC=CC=C1 HDGICZVUXOQTPV-UHFFFAOYSA-N 0.000 description 1
150000008039 phosphoramides Chemical class 0.000 description 1
239000011148 porous material Substances 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
238000012746 preparative thin layer chromatography Methods 0.000 description 1
150000003141 primary amines Chemical class 0.000 description 1
150000003335 secondary amines Chemical class 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000012312 sodium hydride Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
229940124530 sulfonamide Drugs 0.000 description 1
150000003456 sulfonamides Chemical class 0.000 description 1
230000001629 suppression Effects 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000009897 systematic effect Effects 0.000 description 1
150000003566 thiocarboxylic acids Chemical class 0.000 description 1
150000003573 thiols Chemical class 0.000 description 1
150000003585 thioureas Chemical class 0.000 description 1
150000003672 ureas Chemical class 0.000 description 1
150000003673 urethanes Chemical class 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
230000004580 weight loss Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Oncology (AREA)
Pain & Pain Management (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

LU85711A 1983-12-23 1984-12-21 Acylaminomitosanes LU85711A1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US06/564,806 US4642352A (en)	1983-12-23	1983-12-23	Acylamino mitosanes
US56480683		1983-12-23

Publications (1)

Publication Number	Publication Date
LU85711A1 true LU85711A1 (fr)	1985-09-12

Family

ID=24255968

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LU85711A LU85711A1 (fr)	1983-12-23	1984-12-21	Acylaminomitosanes

Country Status (32)

Country	Link
US (1)	US4642352A (de)
JP (1)	JPS60169481A (de)
KR (1)	KR910009329B1 (de)
AR (1)	AR244231A1 (de)
AT (1)	AT386828B (de)
AU (1)	AU561376B2 (de)
BE (1)	BE901377A (de)
CA (1)	CA1239645A (de)
CH (1)	CH665641A5 (de)
DD (1)	DD228259A5 (de)
DE (1)	DE3447003C2 (de)
DK (1)	DK169477B1 (de)
ES (1)	ES8603485A1 (de)
FI (1)	FI81099C (de)
FR (1)	FR2557112B1 (de)
GB (1)	GB2151627B (de)
GR (1)	GR82567B (de)
HU (1)	HU193245B (de)
IE (1)	IE57835B1 (de)
IL (1)	IL73876A (de)
IT (1)	IT1178792B (de)
LU (1)	LU85711A1 (de)
MY (1)	MY100976A (de)
NL (1)	NL8403852A (de)
NO (1)	NO163570C (de)
NZ (1)	NZ210254A (de)
OA (1)	OA07911A (de)
PT (1)	PT79741B (de)
SE (1)	SE8406577L (de)
SU (1)	SU1364239A3 (de)
YU (1)	YU45688B (de)
ZA (1)	ZA849907B (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4487769A (en) *	1982-06-04	1984-12-11	Bristol-Myers Company	Amidines
NZ206932A (en) *	1983-02-07	1987-08-31	University Patents Inc	Certain 6-(heterocyclyl or amino) mitosanes and pharmaceutical compositions
US4803212A (en) *	1983-04-11	1989-02-07	Bristol-Myers Company	Amino disulfides
FR2571373A1 (fr) *	1984-10-09	1986-04-11	Bristol Myers Co	Procede de preparation de derives n7-substitues de la mitomycine c
CA1282069C (en) *	1985-09-12	1991-03-26	Damon L. Meyer	Antibody complexes of hapten-modified diagnostic or therapeutic agents
JPS6354380A (ja) *	1986-08-26	1988-03-08	Kyowa Hakko Kogyo Co Ltd	マイトマイシン誘導体
ZA886812B (en) *	1987-11-23	1989-07-26	Bristol Myers Co	Anti-tumor prodrugs
US4874779A (en) *	1988-06-29	1989-10-17	Bristol-Myers Company	Mitomycin phosphate derivatives
US5214804A (en) *	1992-01-27	1993-06-01	Carey Michael J	Protective mask with scarf

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US27384A (en) *		1860-03-06		Slide-valve for steam-engines
BE655399A (de) *
CA771155A (en) *		1967-11-07	Matsui Masanao	Phosphorus-containing derivatives of mitomycin c
US3660578A (en) *	1957-04-06	1972-05-02	Kyowa Hakko Kogyo Kk	Mitomycin c
NL129868C (de) *	1963-06-07
DE1570029A1 (de) *	1964-07-09	1970-04-09	Kyowa Hakko Kogyo Kk	Verfahren zur Herstellung von Mitosanverbindungen
US3420846A (en) *	1964-08-25	1969-01-07	Kyowa Hakko Kogyo Kk	7-substituted mitomycin a
US3332944A (en) *	1964-11-02	1967-07-25	American Cyanamid Co	Antibiotic derivatives of mitomycins a, b, c and porfiromycin
FR1540921A (fr) *	1965-05-18	1968-10-04	Kyowa Hakko Kogyo Kk	Procédé de préparation de dérivés de thio-urée de la mitomycine c
US3410867A (en) *	1965-11-22	1968-11-12	Kyowa Hakko Kogyo Kk	Mitomycin derivatives
JPS5439098A (en) *	1977-08-31	1979-03-24	Kyowa Hakko Kogyo Co Ltd	Mitomycin c derivatives
EP0008021B1 (de) *	1978-07-18	1984-05-16	Kyowa Hakko Kogyo Co., Ltd	Mitomycine und Verfahren zu ihrer Herstellung
US4268676A (en) *	1979-12-05	1981-05-19	University Patents, Inc.	Mitomycin analogs
US4444768A (en) *	1980-03-04	1984-04-24	Ciba-Geigy Corporation	Pyrimido[1,6-a]indoles, pharmaceutical preparations containing them, and methods of treating pain and inflammation with them
NZ199617A (en) *	1981-05-15	1985-08-30	University Patents Inc	Azirino(2',3',:3,4)pyrrolo(1,2-a)indole-4,7-dione derivatives and pharmaceutical compositions
JPS58201791A (ja)	1982-05-19	1983-11-24	Katsuo Unno	ヘマトポルフイリン誘導体
US4487769A (en) *	1982-06-04	1984-12-11	Bristol-Myers Company	Amidines

1983
- 1983-12-23 US US06/564,806 patent/US4642352A/en not_active Expired - Fee Related
1984
- 1984-11-20 AU AU35710/84A patent/AU561376B2/en not_active Ceased
- 1984-11-20 NZ NZ210254A patent/NZ210254A/en unknown
- 1984-12-06 AR AR84298866A patent/AR244231A1/es active
- 1984-12-11 FR FR8418904A patent/FR2557112B1/fr not_active Expired
- 1984-12-12 CA CA000469874A patent/CA1239645A/en not_active Expired
- 1984-12-19 FI FI845037A patent/FI81099C/fi not_active IP Right Cessation
- 1984-12-19 NL NL8403852A patent/NL8403852A/nl not_active Application Discontinuation
- 1984-12-19 ES ES538804A patent/ES8603485A1/es not_active Expired
- 1984-12-19 ZA ZA849907A patent/ZA849907B/xx unknown
- 1984-12-19 NO NO845100A patent/NO163570C/no unknown
- 1984-12-19 YU YU215284A patent/YU45688B/sh unknown
- 1984-12-20 IL IL73876A patent/IL73876A/xx not_active IP Right Cessation
- 1984-12-20 CH CH6091/84A patent/CH665641A5/de not_active IP Right Cessation
- 1984-12-21 SE SE8406577A patent/SE8406577L/xx unknown
- 1984-12-21 SU SU843826167A patent/SU1364239A3/ru active
- 1984-12-21 GR GR82567A patent/GR82567B/el unknown
- 1984-12-21 OA OA58488A patent/OA07911A/xx unknown
- 1984-12-21 DK DK621484A patent/DK169477B1/da active
- 1984-12-21 GB GB08432513A patent/GB2151627B/en not_active Expired
- 1984-12-21 DD DD84271473A patent/DD228259A5/de not_active IP Right Cessation
- 1984-12-21 BE BE0/214237A patent/BE901377A/fr not_active IP Right Cessation
- 1984-12-21 LU LU85711A patent/LU85711A1/fr unknown
- 1984-12-21 JP JP59268757A patent/JPS60169481A/ja active Granted
- 1984-12-21 HU HU844801A patent/HU193245B/hu not_active IP Right Cessation
- 1984-12-21 PT PT79741A patent/PT79741B/pt not_active IP Right Cessation
- 1984-12-21 IT IT24227/84A patent/IT1178792B/it active
- 1984-12-21 IE IE3318/84A patent/IE57835B1/en not_active IP Right Cessation
- 1984-12-21 DE DE3447003A patent/DE3447003C2/de not_active Expired - Fee Related
- 1984-12-21 AT AT0407484A patent/AT386828B/de not_active IP Right Cessation
- 1984-12-22 KR KR1019840008275A patent/KR910009329B1/ko not_active Expired
1987
- 1987-09-29 MY MYPI87002232A patent/MY100976A/en unknown

Also Published As

Publication number	Publication date
GB2151627A (en)	1985-07-24
KR850004762A (ko)	1985-07-27
HUT37434A (en)	1985-12-28
IT8424227A0 (it)	1984-12-21
IT1178792B (it)	1987-09-16
ATA407484A (de)	1988-03-15
FI845037L (fi)	1985-06-24
NO845100L (no)	1985-06-24
FI81099C (fi)	1990-09-10
MY100976A (en)	1991-06-15
SE8406577L (sv)	1985-06-24
YU215284A (en)	1990-06-30
DE3447003A1 (de)	1985-07-04
FI845037A0 (fi)	1984-12-19
FR2557112A1 (fr)	1985-06-28
HU193245B (en)	1987-08-28
CH665641A5 (de)	1988-05-31
BE901377A (fr)	1985-06-21
ZA849907B (en)	1985-08-28
KR910009329B1 (ko)	1991-11-11
PT79741B (en)	1987-01-16
NZ210254A (en)	1988-02-29
SU1364239A3 (ru)	1987-12-30
US4642352A (en)	1987-02-10
FI81099B (fi)	1990-05-31
IE57835B1 (en)	1993-04-21
DK621484A (da)	1985-06-24
GB8432513D0 (en)	1985-02-06
ES538804A0 (es)	1985-12-16
IL73876A (en)	1991-08-16
SE8406577D0 (sv)	1984-12-21
CA1239645A (en)	1988-07-26
FR2557112B1 (fr)	1987-02-13
IE843318L (en)	1985-06-23
IL73876A0 (en)	1985-03-31
AU561376B2 (en)	1987-05-07
JPH0471076B2 (de)	1992-11-12
AT386828B (de)	1988-10-25
ES8603485A1 (es)	1985-12-16
NO163570C (no)	1990-06-20
OA07911A (fr)	1986-11-20
YU45688B (sh)	1992-07-20
AU3571084A (en)	1985-06-27
GR82567B (en)	1985-04-23
PT79741A (en)	1985-01-01
NO163570B (no)	1990-03-12
GB2151627B (en)	1988-03-30
DK621484D0 (da)	1984-12-21
DE3447003C2 (de)	1994-11-17
NL8403852A (nl)	1985-07-16
AR244231A1 (es)	1993-10-29
DK169477B1 (da)	1994-11-07
JPS60169481A (ja)	1985-09-02
DD228259A5 (de)	1985-10-09

Publication	Publication Date	Title
EP0399856B1 (de)	1995-08-09	Pteridin-4 (3H)-onen, Verfahren zu ihrer Herstellung und sie enthaltende Medikamente
HK1002935B (en)	1998-09-25	Pyrrolopyrimidine derivatives with antiproliferative action
HK1002935A1 (en)	1998-09-25	Pyrrolopyrimidine derivatives with antiproliferative action
EP2845855A1 (de)	2015-03-11	Neue heterozyklische Stickstoffverbindungen, ihre Herstellung und ihre Verwendung als antibakterielle Medikamente
FR2626002A1 (fr)	1989-07-21	Nucleosides dideoxydidehydrocarbocycliques et composition pharmaceutique les contenant
JPWO1988000944A1 (ja)	1988-06-02	血管新生阻害剤
EP1840125A2 (de)	2007-10-03	Derivate von Dioxan-2-alkylcarbamaten, deren Herstellung und deren Anwendung in der Krankenbehandlung
LU86600A1 (fr)	1987-04-02	Produits d'echange entre un aminodisulfure et un thiol
BE1000573A4 (fr)	1989-02-07	Derives de 1-(hydroxystyryl)-5h-2,3-benzodiazepine, procede pour les preparer et compositions pharmaceutiques les contenant.
FR2557112A1 (fr)	1985-06-28	Acylamino mitosanes
EP0303871B1 (de)	1992-12-09	Oxadiazol-pyrimidinone, ihre Herstellung und ihre kosmetische und dermopharmazeutische Verwendung
EP2020410B1 (de)	2013-12-18	Pyrido[2,3-d]pyrimidinderivate,Verfahren zu deren Herstellung und ihre therapeutische Verwendung
FR2543953A1 (fr)	1984-10-12	Analogue de la mitomycine comportant un groupe disulfure, leur preparation et leur application pharmacologique
FR2483929A1 (fr)	1981-12-11	Nouvelles adenosines n6-substituees utiles comme medicaments antihypertenseurs, compositions therapeutiques et formes pharmaceutiques les contenant, et leur procede de preparation
EP0210896B1 (de)	1990-10-10	Optisch reine 4-Amino-3-hydroxy-carbonsäure-Derivate und Verfahren zur Stereospezifischen Herstellung
EP0115713B1 (de)	1987-08-05	2-(1-Piperazinyl)-Pyrimidine, ihre Salze, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammenstellungen
FR2569696A1 (fr)	1986-03-07	Nouveaux analogues de la mitomycine, leur procede de preparation et leur application pharmaceutique
EP0294258A1 (de)	1988-12-07	Hydrazin-Derivate, Verfahren zu deren Erhaltung und diese enthaltende pharmazeutische Zusammensetzungen
FR2477142A1 (fr)	1981-09-04	Nouveaux derives de la nitrosouree, leur procede de preparation et leur application en therapeutique
EP0061397A1 (de)	1982-09-29	Lösliche, N2-substituierte Derivate von 2,4-Diamino-5-benzyl-pyrimidinen, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
FR2465739A1 (fr)	1981-03-27	Cephalosporines, leurs procedes de preparation et compositions pharmaceutiques en contenant
LU86411A1 (fr)	1986-11-05	Procede de preparation de derives n7-amidino-substitutes de la mitomycine c.
WO2006051202A1 (fr)	2006-05-18	Derives de 4,7-dioxobenzothiazole-2-carboxamides, leur preparation et leurs applications therapeutiques
EP0196943A1 (de)	1986-10-08	8-Thiotetrahydrochinoleinderivate und deren Salze
FR2677477A1 (fr)	1992-12-11	Nouveaux derives de l'oxazole leur preparation, leur utilisation et les compositions pharmaceutiques qui les contiennent.